WO2020175697A1 - 3,5-二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 - Google Patents
3,5-二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 Download PDFInfo
- Publication number
- WO2020175697A1 WO2020175697A1 PCT/JP2020/008509 JP2020008509W WO2020175697A1 WO 2020175697 A1 WO2020175697 A1 WO 2020175697A1 JP 2020008509 W JP2020008509 W JP 2020008509W WO 2020175697 A1 WO2020175697 A1 WO 2020175697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- salt
- present disclosure
- pembrolizumab
- pyrazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure relates to an antitumor agent, an antitumor effect enhancer, and a kit preparation.
- Fibroblast growth factor (FG F; fibroblast growth factor) is expressed in a wide range of tissues and is one of the growth factors that governs proliferation and differentiation of cells.
- the physiological activity of FG F is mediated by a specific cell surface receptor, the fibroblast growth factor receptor (FG FR).
- FGFR belongs to the receptor-type protein tyrosine kinase family and is composed of an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain, and four types of FGFR have been identified so far. (FG FR 1, FG FR 2, FGFR 3 and FGFR 4).
- FGFR forms a dimer upon binding of FGF and is activated by phosphorylation.
- Receptor activation induces the recruitment and activation of specific downstream signaling molecules and exerts physiological functions.
- Abnormal FGF/FGFR signaling has been reported to be associated with various human tumors.
- Abnormal activation of FGF/FGFR signals in human tumors is caused by overexpression of FG FR and/or gene amplification, gene mutation, chromosomal translocation/insertion/inversion, gene fusion or FGF as a ligand.
- overproduction ⁇ 02020/175697 2 (: 17 2020 /008509
- Non-Patent Documents 1, 2, 3 and 4 are non-Patent Documents 1, 2, 3 and 4.
- cancer immunotherapy is being developed as one of new cancer treatment methods.
- Nivolumab (human type 9084 monoclonal antibody against human oral cavity _ 1) is used as an immune checkpoint inhibitor that activates Ding cells by inhibiting the binding of Escherichia coli to the treatment of malignant melanoma (Patent Document 1, Non-Patent Document 6). Further, bembrolizumab is an immune checkpoint inhibitor having a different antibody type from nivolumab, and is used for the treatment of malignant melanoma, non-small cell lung cancer, etc. (Non-Patent Document 6).
- Examples of the use of immune checkpoint inhibitors and FGFR inhibitors include, for example, Pd-1 or P in the phase I clinical trial (NCTO 2365597) of erdafitinib (JNJ-42756493) for urothelial cancer.
- Studies of FGFR inhibitors in subjects with DL 1 pretreatment have been reported.
- a combined use trial of anti-FGFR3 antibody V ⁇ fatamab and pembrolizumab is in progress (NCT 03 1 23055).
- Non-Patent Document 1 2 As continuous administration, there are reports of combined use of pazopanib, which is a multikinase inhibitor with FGFR inhibitory effect, and everolimus, combined use of V ⁇ datamab and docetaxel, and continuous administration of atezolizumab (Non-Patent Document 1 2 ).
- Patent Document 1 International Publication 2004/00477 No. 1
- Patent Document 2 International Publication 201 3/1 08809
- Patent Document 3 International Publication 201 7/1 50725
- Patent Document 4 International Publication 201 6/1 6 1 239
- Non-Patent Document 1 N a t .R e v. C a n c e r 1 0 :1 1 6— 1 29 (20
- Non-Patent Document 2 J. Cli n. O ncol. 24, 3664-367 1 (2006)
- Non-Patent Document 3 Mo l .C a n c e r R e s. 3, 655— 667
- Non-Patent Document 4 C a n c e r R e s. 70, 2085 -2094 (20
- Non-Patent Document 5 N a t .R e v. C a n c e r, 1 2 :252-264 (20 1 2)
- Non-Patent Document 6 N. E n g l .J .Me d., 366: 2443-2454 (201 2)
- Non-Patent Document 7 T h e B r e a s t .37, 1 26-1 33 (201 8)
- Non-Patent Document 8 ⁇ n c o t a r g e t .8: 1 6052 — 1 6074 (20
- Non-Patent Document 9 Cel I .1 68: 707 -723 (201 7)
- Non-Patent Document 10 N. E n g l .J .Me d., 375: 81 9-829 (2 01 6)
- Non-Patent Document 11 S c i .T r a n s I .Me d. 9, e a a I 3604 (2 01 7)
- Non-Patent Document 12 J C ⁇ P r e c i s i o n ⁇ n e o l o g y (D ⁇ l:
- Non-Patent Document 13 Ce l I u I a r P h y s i o l o g y a n d B i o c h e m i s t r y, 33, p .633— 645 (201 4)
- Non-Patent Document 14 f r o n t i r s i n I mm u n o l o g y, 9, 20 1 8, A r t i c l e 1 3 1 0.d o i :1 0. 3389/f i mm u. 2 01 8. 01 3 1 0
- the present disclosure provides (S) — 1 — (3 — (4-amino-3_ ((3, 5-dimethoxyphenenyl) ethynyl) _ 1 H-pyrazolo [3, 4-d] pyrimidine-1 _. ⁇ 02020/175697 5 ⁇ (: 171-1? 2020 /008509
- a compound having an inhibitory activity is (3)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl). ) 1 1 to 1—pyrazolo [3, 4—] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one (hereinafter also referred to as “compound 1”) or a salt thereof is used as an immune checkpoint. It was found that the above problem can be solved by using it together with an inhibitor.
- Item 1 (3)-1-(3- (4-amino-3-((3,5-dimethoxyphenyl)ethynyl)) Pyrazolo [3,4_]pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one or its salts as an active ingredient in patients with cancer resistant to immune checkpoint inhibitors and with bembrolizumab Antitumor agent that is co-administered.
- Item 2 The antitumor agent according to Item 1, wherein the tumor has an abnormality in the ⁇ pathway.
- Item 3 The antitumor agent according to Item 2, which is at least one member selected from the group consisting of abnormal genes and abnormal signal states.
- Item 4 The antitumor agent according to any one of Items 1 to 3, wherein the treatment with the antitumor agent causes a sustained response in an individual after the treatment is stopped.
- Item 7. (3)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)) Any of paragraphs 1-6, wherein pyrazolo[3,4_]pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one or salt thereof and pembrolizumab are administered in treatment with the same therapeutic regimen 1
- Item 7 The antitumor agent according to any one of items 1 to 7.
- Item 10 The antitumor agent according to Items 1 to 9, wherein the tumor resistant to the immune checkpoint inhibitor is esophageal cancer or non-small cell lung cancer.
- Item 1 Pembrolizumab and (3)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)) 1 1 ⁇ 1-pyrazolo [3, 4—] Pyrimidin-1-yl) Pyrrolidin-1-yl) Proper-2-en-1-one or a salt thereof as an active ingredient.
- Item 12 The pharmaceutical composition according to Item 11 for treating cancer that is resistant to an immune checkpoint inhibitor.
- Item 1 Pembrolizumab and (3)-1-(3-(4-amino-3_ (((()) for producing an antitumor agent for treating a cancer resistant to an immune checkpoint inhibitor.
- Item 1 4. (3) — 1-(3-(4-amino-3 — for the manufacture of an antitumor agent to be co-administered with bembrolizumab in patients with resistance to immune checkpoint inhibitors Use of ((3,5-dimethoxyphenyl)ethynyl)pyrazolo [3,4d pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof.
- Item 15 For patients with resistance to immune checkpoint inhibitors, (3)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)) 1 1 1 ⁇ !—Pyrazolo [3,4—]pyrimidin-1-yl) Pyrrolidin-1-yl) Proper-2-en-1-one or the use of pembrolizumab for the manufacture of an antitumor agent to be co-administered with a salt thereof.
- Paragraph 1 Pembrolizumab and (3)-1-(3-(4-amino-3 — ((3, 5— for the use of it in the treatment of cancers resistant to immune checkpoint inhibitors. Dimethoxyphenyl) ethynyl) 1 1 to 1-pyrazolo [3, 4 -] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or a salt thereof. ⁇ 02020/175697 8 ⁇ (: 171? 2020 /008509
- Paragraph 1 (3)-1-(3-(4—amino-3_ ((3, for the use of combination therapy with bembrolizumab in the treatment of cancers resistant to immune checkpoint inhibitors. 5-dimethoxyphenyl)ethynyl) _ 1 1 to 1_ pyrazolo [3, 4_] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or a salt thereof.
- Item 18 In the treatment of cancer resistant to immune checkpoint inhibitors (3)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)) Pembrolizumab for use in combination therapy with 1 1 to 1—pyrazolo [3,4—] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or a salt thereof.
- Item 1 Pembrolizumab and (3)-1-(3-(4-amino-3-((3, 5-dimethoxyphenyl)) for treating cancers resistant to immune checkpoint inhibitors Ethynyl) 1 1 to 1—pyrazolo [3, 4—] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-!-one or salt thereof.
- Item 2 Cancers resistant to immune checkpoint inhibitors (3) —
- Item 22 A method for treating cancer resistant to an immune checkpoint inhibitor, comprising a therapeutically effective amount of (3)-1-(3-(4-amino-3-((3, 5 Toxiphenyl) Ethinyl) 1 1 1!—Pyrazolo [3, 4—] ⁇ 02020/175697 9 ⁇ (: 171? 2020 /008509
- Limidin-1-yl) pyrrolidin-1-yl) proper-2-en-!-one or a salt thereof and a therapeutically effective amount of bembrolizumab are administered to a human in need thereof.
- Item 23 (3)-1-(3- (4-amino- 3- ((3, 5-dimethoxyphenyl) ethynyl)) 1 1 ⁇ 1—pyrazolo [3, 4—] pyrimidine-1 — y Le) Pyrrolidin-1-yl) Proper-2-en-1-one or a salt thereof as an active ingredient, an antitumor agent that is co-administered with bembrolizumab to cancer patients who have not been administered with immune checkpoint inhibitors.
- Item 24 Pembrolizumab and (3)-1-(3-(4-amino- 3- ((3, 5-dimethoxyphenyl) ethynyl) 1 1 ⁇ 1-pyrazolo [3, 4 -] pyrimidine- 1-yl) Pyrrolidin-1-yl) Prop-2-en-1-one or a pharmaceutical composition for treating cancer in a cancer patient who has never been administered with an immune checkpoint inhibitor containing the salt thereof as an active ingredient.
- Item 25 The pharmaceutical composition according to Item 24, for treating cancer having resistance to an immune checkpoint inhibitor.
- Item 26 Bembrolizumab and (3)-1-(3-(4 4) for producing an antitumor agent for treating cancer in a cancer patient who has not been administered with an immune checkpoint inhibitor. -Amino-3-((3,5-dimethyoxyphenyl)ethynyl)-1 1!!—Pyrazolo [3,4—]pyrimidin-1-yl) Pyrrolidin-1-yl)proper-2-ene-1-one or its salt Use of.
- Item 27 (3) — 1-(3-(4-amino-acid for producing an anti-tumor agent to be co-administered with bembrolizumab for cancer patients who have not been administered with immune checkpoint inhibitor.
- Use of 3_ ((3,5-dimethoxyphenyl)ethynyl)pyrazolo [3,4d pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one or a salt thereof.
- Paragraph 28 (3)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)) 1 for cancer patients who have not been treated with immune checkpoint inhibitors. 1!—Pyrazolo [3, 4—] Pyrimidin 1-yl) Pyro ⁇ 02020/175697 10 ⁇ (: 171? 2020 /008509
- pembrolizumab for the manufacture of an antitumor agent to be administered in combination with lysine-1-yl)prop-2-en-1-one or a salt thereof.
- Item 29 Bembrolizumab and (3)-1-(3-(4-amino-3_ ((3, 5-dimethoxyphenyl)ethynyl) 1 1 to 1_ pyrazolo [3, 4_] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or a combination thereof with a salt.
- Item 30 For use by combination therapy with pembrolizumab in the treatment of cancer in a cancer patient who has not administered an immune checkpoint inhibitor (3) — 1 — (3-(4— Amino-3— ((3,5-dimethyoxyphenyl)ethynyl) 1 1 1 to 1-pyrazolo [3, 4 d Pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or a salt thereof.
- Item 3 1. In the treatment of cancer in cancer patients who have not been administered with immune checkpoint inhibitors (3) — 1 — (3— ((3, 5 — Dimethoxyphenyl) ethynyl) 1 1 ⁇ 1 — Pyrazolo [3, 4—] Pyrimidin — 1 — yl) Pyrrolidin 1 — yl) Proper 2-en-1 — one or its salt Pembrolizumab for use with therapy.
- Item 32 Bembrolizumab and (3)-1-(3-(4-amino 3-((3, Use of 5-dimethoxyphenyl)ethynyl) 1 !-pyrazolo [3,pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or salts thereof.
- Item 33 ( 3 )-1-(3-(4—amino-3_ (((()) for treating cancer in a cancer patient who has never been administered with an immune checkpoint inhibitor by combination therapy with bembrolizumab.
- Item 34 For cancer patients who have not been administered with immune checkpoint inhibitors ⁇ 02020/175697 11 ⁇ (: 171? 2020 /008509
- Item 35 A method for treating cancer in a cancer patient who has not been administered with an immune checkpoint inhibitor, wherein a therapeutically effective amount of (3)-1-(3-(4-amino acid 3 — ((3,5-Dimethoxyphenyl)ethynyl)-1 !!—Pyrazolo [3,pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one or its salt and a therapeutically effective amount of pembrolizumab And administering to a human in need thereof.
- Item 36 The composition according to any one of Items 11 to 22, wherein the tumor has an abnormality in the ⁇ pathway, use, combination, (3)-1-(3-(4-amido) No 3—((3,5-dimethoxyphenyl)ethynyl) 1 !!—pyrazolo [3,pyrimidin 1-yl)pyrrolidin 1-yl)proper 2-en-1-one or salt thereof, vembolizumab, or method.
- composition, use and combination according to Item 36 which is at least one member selected from the group consisting of gene abnormality and signal abnormal state, (3)-1-(3-(4-amino-3 — ((3,5—Dimethoxyphenyl)ethynyl) 1 1!!-Pyrazolo [3, Pyrimidin-1-yl) Pyrrolidin-1-yl) Proper-2-en-1-one or a salt thereof, pembrolizumab, or a method.
- Item 38 (3)-1-(3-(4-amino- 3- ((3, 5-dimethyoxyphenyl) ethynyl)) 1 1 ⁇ 1—pyrazolo [3, 4—] pyrimidine-1 — y Le) Pyrrolidin-1-yl) Proper-2-en-1-one or a salt thereof as an active ingredient, resistant to immune checkpoint inhibitors, and used in combination with Vembrolizumab for cancer patients who have no abnormality in the pathway Antitumor agent to be administered. ⁇ 02020/175697 12 ⁇ (: 171-1? 2020 /008509
- Item 39 Pembrolizumab and (3)-1-(3-(4-amino- 3- ((3,5-dimethoxyphenyl)ethynyl)) 1 1 ⁇ 1-pyrazolo [3, 4-] pyrimidine- 1-yl) Pyrrolidin-1-yl) proper-2-en-1-one or a salt thereof as an active ingredient
- a pharmaceutical composition for treating cancer having no abnormality in the pathway
- Item 40 The pharmaceutical composition according to item 24, which is for treating a cancer having resistance to an immune checkpoint inhibitor.
- Item 4 Bembrolizumab and (3)-1-(3-(4-amino-3-((3 Use of 1,5-dimethoxyphenyl)ethynyl) 1 1 to 1—pyrazolo [3,4 -]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or salts thereof.
- Item 42 ⁇ (3)-1-(3-(4-Amino 3-(for the production of an antitumor agent to be co-administered with bembrolizumab for cancer patients who do not have abnormality in the pathway.
- Item 43 cancer patients without abnormalities to the ⁇ path, (3) _ 1 _ (3 - (4-amino-3_ ((3, 5-dimethyl Tokishifueniru) ethynyl) one 1 11 - pyrazolo [3,4-]Pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one or the use of pembrolizumab for the manufacture of an antitumor agent to be administered in combination with a salt thereof.
- Item 44 ⁇ (3)-1-(3-(4-amino-3-((3, 5-dimethoxyphenyl) ethynyl) with pembrolizumab for use in the treatment of cancers that do not have pathological abnormalities. ) Ichi 1!!—Pyrazolo [3, 4—] Pyrimidin-1-yl) Pyrrolidin-1-yl) Proper-2-en-1-one or a combination with a salt thereof.
- Item 47 ⁇ Bembrolizumab and (3)-1-(3-(4-amino-3-((3, 5-dimethoxyphenyl)ethynyl) for treating cancers that do not have abnormal pathways) Use of pyrazolo [3, 4_] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or a salt thereof.
- Item 48 (3)-1-(3-(4-amino- 3- ((3, 5 -dimethoxyphenyl)) for treating a cancer having no abnormality in the pathway by a combination therapy with bembrolizumab Ethynyl) 1 1 to 1—pyrazolo [3, 4—] pyrimidin-1-yl) pyrrolidin-1-yl) proper-2-en-1-one or use of its salt.
- Item 50 A method for treating cancer having no abnormality in the pathway, wherein a therapeutically effective amount of (3) — 1 — (3— (4-amino-3 — ((3, 5-dimethoxyphenyl) ) Ethinyl) Pyrazolo[3,4_]pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one or a salt thereof and a therapeutically effective amount of pembrolizumab may be administered to a human in need thereof.
- ⁇ 02020/175697 14 (: 171? 2020 /008509
- Item 5 The composition according to any one of Items 11 to 50, wherein the treatment with Compound 1 or a salt thereof and pembrolizumab results in a sustained response in the individual after the treatment is stopped.
- Proper 2-en-1 -year-old or salt thereof bembrolizumab, or method.
- Item 52 The composition according to any one of Items 11 to 51, wherein Compound 1 or a salt thereof is used before pembrolizumab, used simultaneously with pembrolizumab, or used after bembrolizumab. Substance, use, combination, (3)-1-(3- (4-amino-3_((3,5-dimethyoxyphenyl)ethynyl)) 1 1 ⁇ 1_ pyrazolo [3, 4_] pyrimidine-1-yl) pyrrolidin 1-yl) proper 2-en-1-one or salt thereof, vembolizumab, or method.
- Item 53 The composition, use, combination, (3)-1 according to any one of Items 11 to 52, wherein Compound 1 or a salt thereof is used continuously or intermittently.
- Item 54 (3)-1-(3-(4-amino- 3- ((3, 5-dimethyoxyphenyl) ethynyl)) 1 1 ⁇ 1—pyrazolo [3, 4—] pyrimidine-1 — y Le) pyrrolidin-1-yl) prop-2-en-1-one or a salt thereof and vemlolizumab are administered in the treatment with the same therapeutic regimen,
- FIG. 1 Results of Example 2 (Bone marrow-derived immunosuppressive cells (Effect of Compound 1 on).
- the present disclosure provides: a combination of a compound having an inhibitory activity and an immune checkpoint inhibitor, that is, an antitumor agent that is co-administered with an immune checkpoint inhibitor, including a compound having an inhibitory activity, An antitumor effect enhancer containing a compound having an activity, a compound having an inhibitory activity and an immunochemical effect ⁇ 0 2020/175697 16 ⁇ (: 171-1? 2020 /008509
- the present invention relates to the provision of a compound having an inhibitory activity in the manufacture of a medicament for the treatment of a tumor, which is carried out in combination with an immunological checkpoint inhibitor, in combination with an immune checkpoint inhibitor.
- an excellent antitumor effect is brought about by the combined use with an immune checkpoint inhibitor (3) — 1 — (3— (4-amino-3 — ((3,5-dimethoxyphenyl)ethynyl) ) 1 1 !!—Pyrazolo [3,4—]pyrimidin-1-yl)pyrrolidin-1-yl)proper-2-en-1-one is a disubstituted benzenealkynyl compound having the following structure.
- the above compound is referred to as “Compound 1” for convenience.
- Compound 1 is described as Example Compound 2 in Patent Document 2 above.
- Compound 1 or a salt thereof has an excellent ⁇ inhibitory action, It has been reported that [3 ⁇ 4 4] inhibits the phosphorylation ability of thyrosin in the substrate peptide sequence of its respective receptor protein tyrosine kinase (Patent Document 2).
- Compound 1 or a pharmaceutically acceptable salt thereof in the present disclosure described above is particularly limited. Although not specified, it can be synthesized based on the production method described in Patent Document 2, for example.
- Compound 1 can be used as it is or in the form of a pharmaceutically acceptable salt.
- the pharmaceutically acceptable salt of Compound 1 is not particularly limited, and examples thereof include inorganic acids such as hydrochloric acid and sulfuric acid, addition salts with organic acids such as acetic acid, citric acid, tartaric acid and maleic acid, potassium, Examples thereof include salts with alkali metals such as sodium, salts with alkaline earth metals such as calcium and magnesium, ammonium salts, salts with organic bases such as ethylamine salts and arginine salts.
- the immune checkpoint inhibitor according to the present disclosure has an action of acting on an immune checkpoint molecule, inducing an antitumor immune response in a living body of a subject, and controlling an immune escape of a tumor.
- Examples of such substances include a substance that promotes the function of a costimu atory molecule (stimulatory costimulatory molecule), or a function of a c ⁇ inhibit ⁇ ry molecule (an inhibitory costimulatory molecule). Examples include substances that suppress.
- immune check point molecules examples include B 7 f am ily (B 7 -1, B 7 -2, P DL 1, P DL 2 etc.), CD 28 f am i I y (CT LA -4, P D-1 etc.), TN F superf am i I y (4-1 BBL, OX 40 L), TN F receptor superf am i I y (4-1 BB, 0X40) molecules, and immune checkpoint inhibitors are Substances targeted to immune checkpoint molecules can be used. Examples thereof include PD-1 pathway antagonists, ICOS pathway agonists, CTLA-4 pathway antagonists, CD28 pathway agonists, BTLA pathway antagonists, and 4-1BB pathway agonists.
- a PD-1 pathway antagonist inhibits an immunosuppressive signal caused by PD-1 expressed on T cells or its ligand PD-L1 or PD-L2.
- antibodies include immunoglobulins (IgA, IgD, IgE, IgG,
- I gM, I g Y etc. F ab fragment, F (ab') 2 fragment, single chain antibody fragment (sc FV), single domain antibody, D iab ⁇ dy etc. (N at .R e v. I mm unol., 6:343—357, 2006), and examples thereof include human antibodies, humanized antibodies, chimeric antibodies, mouse antibodies, llama antibodies, chicken antibodies, and other monoclonal or polyclonal antibodies.
- it is a humanized g G monoclonal antibody or a human g g monoclonal antibody.
- agonists or antagonists can be produced by a generally known production method.
- the anti-PD-1 antibody is already sold as pembrolizumab, and this can also be used.
- the immune checkpoint inhibitors may be used alone or in combination of two or more.
- an immune checkpoint inhibitor such as an anti-PD_1 antibody or an anti-CTLA-4 antibody may be used in combination.
- Bispecific antibodies capable of binding to different immune checkpoint molecules can also be used.
- XmA b 207 17 P D-1 XCT LA-4
- P D-1 XCT LA-4 an antibody capable of binding to both P D-1 and CT LA-4.
- the treatment in the present disclosure includes a treatment for the purpose of curing or ameliorating a disease, or for the purpose of suppressing the progression or relapse of a disease or alleviating the symptoms.
- Treatment may include administration of drugs before or after surgical treatment, or radiation therapy. This includes administration of the drug before or after.
- Antibodies and Compound 1 or salts thereof that block the interaction between a therapeutically effective amount of an immune checkpoint molecule can be associated with, without limitation, the stage and severity of the cancer, as well as the health of the patient. Depends on several factors, including some others. One of ordinary skill in the art would know how to determine a therapeutically effective amount.
- FGFR is selected from the group consisting of FGFR1, FGFR2, FGFR3, and FGFR4.
- a tumor having an abnormality in the FGFR pathway is preferable.
- Abnormalities in the FGFR pathway include overexpression of FGFR, abnormalities of the FGFR gene, and abnormal states of the FGFR signal.
- the present disclosure is, in one aspect, preferably administered to a subject having an abnormality in the FGFFR pathway, regardless of the presence or absence of an abnormality in the FGFFR.
- Compound 1 can promote the antitumor effect of immune checkpoint inhibitors even in carcinomas without FGFR gene abnormality. It is known that the sensitivity of cancer to immune checkpoint inhibitors is also affected by the cancer microenvironment.
- the microenvironment includes, but is not limited to, cancer associated fibro b I ast (CAF) and other populations of cells that are regulated by FG F/FG FR pathway activation, and these populations are sensitive to cancer immune checkpoint inhibitors. It is known to diminish. It is considered that administration of Compound 1 promotes the effects of cancer immune checkpoint inhibitors by causing changes in the microenvironment including inactivation of CAF.
- CAF cancer associated fibro b I ast
- Overexpression of FG FR includes, for example, gene expression and high expression of gene product protein.
- the presence or absence of FG FR expression can be detected by methods known to those skilled in the art.
- Detection of gene expression and high expression of gene product protein is carried out by a known method, for example, a method using an antibody (immunohistological staining, enzyme immunoassay Method (EL ⁇ SA), flow cytometry, immunoblotting, etc.), methods using nuclear acids (insituhybridization, PCR, Northern blotting, etc.), and methods based on common principles.
- the detection device may be a known device (Genechip, microarray, etc.).
- the present disclosure is used, in one embodiment, for a tumor having an abnormality of the FGFR gene.
- Gene abnormalities in the FGFR pathway include gene amplification, gene mutation, chromosomal translocation/insertion/inversion, gene fusion, and gene rearrangement. Abnormalities of the FGFR gene in tumors have already been reported in the literature, some of which are available to those skilled in the art (Non-patent Documents 7 and 8).
- FG FR gene abnormalities can be detected by methods known to those skilled in the art, such as pyrosequencing, DNA sequencing including NGS (next generation sequencing), PCR-based methods including allele-specific PCR chain reactions, microarray-based methods. It can be detected by comparative genomic hybridization (aCGH), fluorescent in situ hybridization (FISH), color development in situ hybridization (CISH), and the like.
- the present disclosure is used, in one embodiment, for a tumor in which an FGFR signal is activated.
- FGFR forms a dimer by the binding of FGFR and is activated by phosphorylation, thereby inducing the recruitment and activation of a specific downstream signaling molecule and expressing a physiological function.
- Activation of the FGFR signal can be detected by methods known to those skilled in the art.
- Signal activation can be detected, for example, by detecting FGF which is a substrate of FGFR, biological activity including direct phosphorylation state or enzymatic activity of FG FR which is a phosphorylating enzyme, intracellular activity existing downstream of FGFR signal cascade. Phosphorylation status of substrates and intracellular proteins, detection of biological activity including enzymatic activity, or detection of gene product or gene transcript.
- the tumor to which the present disclosure is applied also includes a tumor having no abnormality in the FGFR pathway. ⁇ 02020/175697 21 ⁇ (: 171? 2020 /008509
- a preferable daily dose of Compound 1 or a salt thereof is, for example, 4019 ⁇ 24019, 1
- the number of administrations per day on the administration day and the dose may be once a day, 49, 8019, 1 2019, 1 6019, 20 etc.
- the preferred number of administrations per day on the administration day and the dose include 89, 1 2019, 1 6019, 20 and the like.
- the preferable number of administrations per day on the administration day and the dose are 1 2 9 and 1 Etc.
- the preferable number of administrations per day on the administration day and the dose are, for example, 29.
- the disclosure relates in some aspects, the stronger cancer types the desired effective (e.g. brain tumor) Compound 1 or higher doses than dose once daily 20 9 of its salts in the case of Including that.
- the daily dose of Compound 1 or a salt thereof is intermittently administered, the dose is, for example, about 2 to 100,000 ⁇ per day of Compound 1 or a salt thereof, and is preferable. Per day More preferably 1 day More preferably 50 to 160 per day
- Examples of the schedule for administration of Compound 1 or a salt thereof include daily administration and intermittent administration.
- “daily administration” includes, for example, an administration schedule in which the schedule is continuously administered for 21 days and one cycle is included, and a drug holiday period may be provided at each completion of one cycle. Good.
- intermittent administration is not particularly limited as long as it satisfies the condition that it is twice or more per week and the administration interval (the number of days between one administration day and the next administration day) is one or more days apart. ..
- Compound 1 or a salt thereof may be administered every 1 to 3 days per cycle (the interval between one administration day and the next administration day). ⁇ 02020/175697 22 ⁇ (: 171-1? 2020 /008509
- the administration schedule is 1 cycle for 4 days, and during 1 4 days included in 1 cycle, Compound 1 or its salt is treated on the 1st, 4th, 8th and 11th days. Administration schedule on day;
- the administration schedule is 1 cycle for 4 days, and among 1 4 days included in 1 cycle, Compound 1 or its salt is treated on the 1st, 3rd, 5th, 7th day. Dosing schedule, administered on eyes, day 9, day 11 and day 13;
- the administration schedule is 1 cycle for 4 days, and within 1 4 days included in 1 cycle, Compound 1 or its salt is treated on the 1st, 3rd, 5th, 8th day.
- the administration schedule and the like are administered on the 1st day, the 10th day and the 12th day.
- Compound 1 or a salt thereof is administered 1609 once a day on the first day, the third day, the fifth day, the eighth day, and the tenth day. And the administration schedule to be administered on the 12th day.
- the amount of compound 1 or a salt thereof can be reduced by 120019, 8019, 56019, >361119, 2419, 161019, 81119.
- the daily dose of bembrolizumab on the day of administration is the recommended dose when bembrolizumab is administered alone from the viewpoint of enhancing the antitumor effect of pembrolizumab by Compound 1 or a salt thereof.
- 30 to 100% is preferable, 50 to 100% is more preferable, 70 to 100% is more preferable, 80 to 100% is more preferable, 90 to 100% is more preferable. And more preferably 100%.
- the preferred dose of pembrolizumab administered alone is once per dose!! (Weight), once 2.
- the preferred daily dose of bembrolizumab of the present disclosure is 1.0 to 2. (Weight), once 2. (Weight) and the like.
- the administration interval of bembrolizumab is preferably 3 to 4 weeks, more preferably 3 weeks.
- the daily dose of Compound 1 or a salt thereof according to the present disclosure on the day of administration, and the daily dose of bembrolizumab, or a preferable combination of the usage and the dose, includes the following:
- Compounds in the present disclosure And bembrolizumab once from 100 to 400.
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once 100-400 ⁇ !
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once 100-200 ⁇ !
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once per 200,000!
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once per 400 000!
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab ⁇ 02020/175697 25 times (: 171? 2020/008509 once ⁇ ⁇ ⁇ 2. (Weight).
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once 2. (Weight).
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab 200019 every 3 weeks.
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab 400019 3 weeks apart.
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once 100-400 ⁇ !
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once 100-200 ⁇ !
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once per 200,000!
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once per 400 000!
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once.! ⁇ ⁇ 2. (Weight).
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab once 2. (Weight).
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab 200019 every 3 weeks.
- Compound 1 or a salt thereof according to the present disclosure is 9 and bembrolizumab 400019 3 weeks apart.
- Examples of the number of administrations per day, the dose, and the daily dose of bembrolizumab of Compound 1 or a salt thereof in the present disclosure, or the combination of the usage and the dose include the following:
- Compound 1 or a salt thereof according to the present disclosure can be administered once daily to 4019 and pembrolizuma
- Compound 1 or a salt thereof in the present disclosure was administered once daily to 8019 and pembrolizuma And pembrolizumab once 100-400019.
- Compound 1 or salt thereof in the present disclosure 1 6019 once a day and vembolizumab once a day 2. (Weight).
- the use ratio of compound 1 or a salt thereof and bembrolizumab in the present disclosure is not particularly limited, but preferably, with respect to 100 parts by mass of compound 1 or a salt thereof, pembrolizumab is contained in an amount of 10 to 10000 mass. Parts, more preferably in the range of 100 to 100 parts by mass.
- the compounding ratio of the compound 1 or a salt thereof in a dosage form containing the compound 1 or a salt thereof is not particularly limited, and, for example, 100 to 100000 mass. %, preferably in the range of 1,000 to 10,000 mass%.
- the compounding ratio of the immune checkpoint inhibitor in the dosage form containing the immune checkpoint inhibitor is not particularly limited, for example, 100 to 100,000 mass%, preferably 1 000 to 10000 mass. It can be appropriately set within the range of %.
- the above-mentioned preferable mixing ratio is a ratio of the active ingredient to the total amount of the dosage form containing the active ingredient and the dosage form not containing the active ingredient. It means not the mixing ratio but the mixing ratio of the active ingredient to the mass of the dosage form containing the active ingredient.
- the compounding ratio of Compound 1 or its salt it means the mass% of Compound 1 or its salt with respect to the mass of only the dosage form containing Compound 1 or its salt.
- the combination therapy of the present invention has not been previously treated with hormone therapy, immunotherapy (such as cancer peptide vaccine therapy), surgery, radiation therapy, or chemotherapeutic agent.
- adjuvant therapy such as cancer peptide vaccine therapy
- surgery such as surgery
- radiation therapy such as radiation therapy
- chemotherapeutic agent Administered to patients, ie, naive patients.
- the combination therapy is administered to a patient who fails to achieve a sustained response after prior treatment with a chemotherapeutic agent.
- the combination therapy of the present invention is administered to a patient who has not been previously treated with an immune checkpoint inhibitor. In another embodiment, the combination therapy is administered to patients who have been treated with an FGFR inhibitor.
- a sustained response means that an immune response against cancer is expanded and maintained by performing immunotherapy such as an immune checkpoint inhibitor.
- the sustained response can be measured, for example, by measuring the binding of immune checkpoint inhibitors to T lymphocytes.
- the "recommended dose” means a dose that provides the maximum therapeutic effect within the range determined by clinical trials and the like that can be safely used without causing serious side effects.
- PMDA Pharmaceuticals and Medical Devices Agency of Japan
- FDA US Food and Drug Administration
- EMA European Medicines Agency
- Dosages are included, with doses approved by the public authority of either PMDA, FDA or EMA being preferred.
- the administration schedule of the antitumor agent of the present disclosure can be appropriately selected depending on the cancer type, disease stage, and the like.
- the first day to 21 days [for example, 3 weeks (21 days)]
- a daily administration schedule is preferable, but a drug holiday may be allowed thereafter, and more preferable. Is daily for 3 weeks (21 days).
- the administration schedule of the immune checkpoint inhibitor is preferably, for example, every 2 weeks to 4 weeks.
- the dosing schedule administered at intervals of 2 weeks, 3 weeks, and 4 weeks is preferable, and more preferably at intervals of 3 weeks.
- the administration of drug A at X-day intervals means that the day when drug A is administered is day 1, the next day is day 2, and the next day is day 3, then drug A Means that the administration of will be day X + 1.
- “1 week”, “2 weeks”, “3 weeks”, and “4 weeks” refer to “7 days”, “14 days”, and “21 days”, respectively.
- the frequency of daily administration of the antitumor agent of the present disclosure may be appropriately selected depending on the cancer type, disease stage, and the like. Once daily if preferred in combination with pembrolizumab
- compositions of Compound 1 or a salt thereof and pembrolizumab may be appropriately selected depending on the cancer type, stage of disease, etc., but in any one treatment regimen, whichever is administered first or simultaneously. I do not care.
- compound 1 or a salt thereof is vembolizumab. ⁇ 0 2020/175697 31 ⁇ (: 171? 2020 /008509
- pembrolizumab enhances the action of Compound 1 or a salt thereof.
- It is preferably administered to a subject expressing 50% or more.
- ⁇ _ 1 _ 1 expression refers to I 1 to 1 (3 anti-human 0 _ !_ 1 antibody for diagnosis, or an antigen-binding fragment thereof for diagnostic use in a tumor sample or a frozen tissue section of a tumor sample taken from a patient.
- the doctor will use a tumor tissue sample collected from the subject before the start of the combined administration of the immune checkpoint inhibitor and the inhibitor.
- the physician may order diagnostic tests after the start of treatment, for example at the end of the treatment cycle, before treatment or before treatment. Is assumed.
- cancer refers to a physiological condition of a mammal characterized by unregulated cell growth.
- Cancer includes solid cancer and hematological cancer. Examples include, but are not limited to, carcinomas, lymphomas, leukemias, blastomas, sarcomas, borderline malignancies (carcinoids).
- Cancers to which the combination method of the present disclosure is applicable include, for example, head and neck cancers, gastrointestinal cancers (esophageal cancer, gastric cancer, duodenal cancer, liver cancer, cholangiocarcinoma (gallbladder/bile duct cancer, etc.), and spleen.
- gastrointestinal cancers esophageal cancer, gastric cancer, duodenal cancer, liver cancer, cholangiocarcinoma (gallbladder/bile duct cancer, etc.)
- cholangiocarcinoma gallbladder/bile duct cancer, etc.
- Cancer urothelial cancer, small intestine cancer, colorectal cancer (colorectal cancer, colon cancer, rectal cancer, etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, mesothelioma (malignant pleural mesothelioma, peritoneal mesothelioma) Tumor, pericardial mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer, uterine cancer (cervical cancer, endometrial cancer, endometrial cancer, etc.), etc.), renal cancer, bladder cancer, prostate cancer, testicular tumor , Skin cancer (malignant melanoma, epidermal cancer, etc.), blood cancer (multiple myeloma, acute myeloid leukemia, etc.), bone and soft tissue tumor, rhabdomyosarcoma, brain tumor, malignant schwannoma, neuroendocrine tumor, thyroid gland Examples include cancer. ⁇ 0 2020/175697 32 ⁇
- bladder cancer, urothelial cancer, gastrointestinal cancer esophageal cancer, gastric cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder/bile duct cancer, etc.), spleen cancer, small intestine cancer, colon cancer (colon Rectal cancer, colon cancer, rectal cancer, etc.), ovarian cancer, head and neck cancer, uterine cancer (cervical cancer, endometrial cancer, etc.), preferably urothelial cancer, esophageal cancer, non-small cell lung cancer.
- the cancer is an esophageal cancer or a non-small cell lung cancer, where the cancer includes not only the primary tumor but also cancer that has metastasized to other organs (liver etc.).
- Anti-neoplastic agents are used for postoperative adjuvant chemotherapy to prevent recurrence after surgical removal of a tumor It may be used for therapy.
- the cancer to be combined is, for example, malignant melanoma, non-small cell lung cancer, Hodoxylymphoma, urothelial cancer, high-frequency microsatellite instability.
- the term "combination (therapy)” is intended to define a therapy that involves the use of a combination of two or more compounds/agents (as defined above).
- the use of “combination (therapy)”, “combination” and “in combination” of a compound/drug in this application refers to the compound/drug administered as part of the same overall therapeutic regimen. obtain.
- the respective doses of the two or more compounds/drugs may be different: each may be administered at the same time or at different times. It is therefore understood that the compounds/agents of the combination may be administered either sequentially (eg before or after) or simultaneously in either the same pharmaceutical formulation (ie together) or different pharmaceutical formulations (ie separately). To be done. In the same formulation, at the same time, as a single formulation, but in different pharmaceutical formulations at the same time, they are non-integral.
- treatment regimen refers to a plan in which the type and amount of drug, period, procedure, etc. in drug treatment are shown in chronological order. It also indicates the administration method, administration order, and administration date. Treatment with one therapeutic regimen may include, for example, simultaneous or simultaneous administration of drugs that are combined on the first day of one cycle. ⁇ 0 2020/175697 33 ⁇ (: 171-1? 2020 /008509
- Examples include a method of starting administration at substantially the same time.
- 3 weeks are set as one cycle, drug 8 is started first, and drug week is started 1 week later.
- a form in which drug 8 is administered substantially simultaneously in one cycle is also one treatment regimen. Included in treatment.
- the administration form of the antitumor agent of the present disclosure is not particularly limited and may be appropriately selected depending on the purpose of treatment. Specifically, oral agents (tablets, coated tablets, powders, granules, kabsel preparations, liquid preparations) Etc.), injections, suppositories, patches, ointments and the like. In the case of Compound 1 or its salt, an oral preparation is preferred. In the case of bembrolizumab, the above-mentioned administration forms can be mentioned, and injections are preferable.
- pembrolizumab which is an active ingredient
- Compound 1 or a salt thereof may be used as an antitumor agent
- a pharmaceutically acceptable carrier may be used depending on the administration form. It may be used as a pharmaceutical composition prepared by a generally known method.
- examples of such carriers include various substances commonly used for ordinary drugs, such as excipients, binders, disintegrants, lubricants, diluents, solubilizers, suspending agents, isotonic agents,! Examples include regulators, buffers, stabilizers, coloring agents, flavoring agents, and flavoring agents.
- the antitumor agent of the present disclosure may be prepared by dividing each active ingredient into a plurality of dosage forms based on the administration form and administration schedule of each active ingredient, or by formulating them into one dosage form.
- each drug product may be manufactured and sold in one package suitable for combined administration, or each drug product may be manufactured and sold in separate packages.
- a pharmaceutical composition containing pembrolizumab and compound 1 or a salt thereof as an active ingredient a preparation in which each active ingredient was divided into a plurality of dosage forms was also formulated into one dosage form.
- each preparation should be packaged in one package suitable for combined administration. Included are those that are grouped together or that each formulation is in a separate package.
- the present disclosure relates to a kit preparation containing an antitumor agent containing Compound 1 or a salt thereof, and an instruction manual that states that Compound 1 or a salt thereof and vembolizumab are co-administered to a cancer patient.
- the “instruction for use” may be any as long as the above-mentioned dose is described, and whether or not it is legally binding, but the above-mentioned dose is recommended. Specific examples include package inserts and pamphlets.
- a kit formulation that includes instructions for use means that even if the instructions for use are printed on the package of the kit formulation, the instructions for use with the antitumor agent are included in the package of the kit formulation. May be enclosed
- Non-Patent Document 13 As a mechanism of action by an FGFR inhibitor and a method of detecting the development of resistance to an immune checkpoint inhibitor, there is a method of examining the regulation of tumor immune microenvironment (Non-Patent Document 13). Not limited.
- CA F Cancer A ssociated fibrob ast
- FG F Fi b r o b I a st A factor that controls cell growth
- F G F R F G F R
- Bone marrow-derived positive cells MDSC (My eoloid-derived suppressor cells)
- MDSC My eoloid-derived suppressor cells
- Non-Patent Document 14 It has been reported that MDSC can contribute to the resistance of patients to immune checkpoint inhibitors, which is a marker that can be a predictive marker of the effects of immune checkpoint inhibitors.
- resistance to an immune checkpoint inhibitor means that no therapeutic effect is expected after administration of an immune checkpoint inhibitor, and at least one clinical evaluation The progression of disease Confirmed condition of the subject, intolerance to immune checkpoint inhibitor, recurrence after administration of immune checkpoint inhibitor, or no experience of immune checkpoint inhibitor treatment, but immune checkpoint inhibitor therapeutic effect Including the state of the target that cannot be expected. In certain embodiments, it also includes not having an effective effect on an immunological checkpoint inhibitor in a pharmacological test, for example, a reaction of a cell line which is considered not to be effective.
- resistance there are natural resistance in which anti-cancer drugs do not show effectiveness from the beginning of treatment, and acquired resistance that leads to exacerbation of cancer as the anti-cancer drugs that were initially effective become ineffective as treatment continues.
- resistance includes both natural resistance and acquired resistance.
- refractory to an immune checkpoint inhibitor means that after administration of the immune checkpoint inhibitor, the immune checkpoint inhibitor shows no effect and does not exert any effect.
- One of the causes of refractory is resistance.
- the antitumor agent of the present disclosure can be used for treating cancer.
- "Anti-tumor effect" when referring to a cancer patient treated by a treatment regimen such as the combination therapy described herein is, for example, PFS (progression-free survival), DCR (disease control rate), DOR (Response duration), OS (overall survival), ⁇ RR (objective response rate), DCR (disease control rate), TT R (time to first response), PR ⁇ s (Patient— Reported O) utc ome s) etc. means at least one evaluation.
- the tumor evaluation for the combination therapy described herein is evaluated by the R EC I ST 1.1 standard (solid cancer effect determination standard), and the antitumor effect is evaluated. Is indicated by SD (stable), PR (partial response), CR (complete response), PD (progress).
- Tumor evaluation of brain tumors can also be performed with standard brain tumor MR I, including before and after augmentation with Gd_MR I (gadolinium (Gd) killer contrast agent.
- Gd_MR I gadolinium (Gd) killer contrast agent.
- Example 1 (3)-1-(3-(4-amino- 3-((3, 5-dimethyoxyphenyl) ethynyl)) 1 1 ⁇ 1—pyrazolo [3, 4—] pyrimidine-1 -Ill) Pyrrolidin-1-yl) Proper-2-en-1-one or a combination of bembrolizumab and its salt in combination with bembrolizumab for cancer immunotherapy resistant cancer (eg, non-small cell lung cancer, esophageal cancer, urothelial cancer)
- cancer immunotherapy resistant cancer eg, non-small cell lung cancer, esophageal cancer, urothelial cancer
- Placebo may optionally be administered as a control, and additional patients may additionally be administered Compound 1 or a salt thereof and/or vembolizumab. In addition, Compound 1 or a salt thereof may be co-administered to patients who have been treated with pembrolizumab.
- the combination use of Compound 1 or a salt thereof and bembrolizumab may bring about an unexpected therapeutic effect from these monotherapy.
- the combination may be found to be more effective than at least one of the measurements of treatment with either alone.
- a synergistic effect can be obtained by using Compound 1 or a salt thereof and bembrolizumab in combination.
- the combination use of Compound 1 or a salt thereof and pembrolizumab may be more effective than either of them: reduction in the number of cancer cells, tumor Size reduction, rate of cancer cell infiltration into peripheral organs Decreased tumor metastasis or reduced rate of tumor growth, overall response rate, or progression-free survival or extended overall survival.
- Mouse breast cancer strain 4T1 was subcutaneously transplanted into 6-week-old male BALB/c AJ c I mice.
- the cell transplantation date was set to D ay 0, and from the next day (D ay 1), Compound 1 was orally administered at a dose of 15 mg/kg/day for 14 consecutive days.
- the lymphocyte cell fraction was isolated from the tumor, spleen, and peripheral blood, and bone marrow-derived immunosuppressive cells (MDSC) (CD 11 b + /G r- 1 + cells), CD 4 positive T cells and CD 8 positive T cells were measured.
- MDSC bone marrow-derived immunosuppressive cells
- a mouse breast cancer cell 4 T 1 subcutaneous transplant tumor model was prepared, drug administration and measurement of each cell were performed in the same manner as above except that the dose of Compound 1 was 30 mg / kg / day. The same operation as above was performed, except that Compound 1 was not administered as Contr O I. The results are shown in Figure 1.
- Compound 1 was significantly (Studentt-test, P ⁇ 0.01) significantly higher in MDSC in the splenic lymphocyte cell fraction than drug-naive C ⁇ ntr ⁇ I at any dose. Reduced. MDSC in the peripheral blood lymphocyte cell fraction showed a dose-dependent decreasing tendency compared to Co n tr o l. Dose dependence of CD 4-positive T cells in peripheral blood lymphocyte cell fraction, spleen lymphocyte cell fraction, and CD 8-positive T cells in peripheral blood lymphocyte cell fraction compared to C ⁇ ntr ⁇ ⁇ Showed an increasing trend.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/434,655 US20220184082A1 (en) | 2019-02-28 | 2020-02-28 | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab |
JP2021502662A JPWO2020175697A1 (ja) | 2019-02-28 | 2020-02-28 | |
KR1020217030410A KR20210131387A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법 |
AU2020229714A AU2020229714A1 (en) | 2019-02-28 | 2020-02-28 | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab |
EP20763687.9A EP3932427A4 (en) | 2019-02-28 | 2020-02-28 | CANCER THERAPY WITH 3,5-DISUBSTITUTED BENZENE-ALKYNYL COMPOUND AND PEMBROLIZUMAB |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-035603 | 2019-02-28 | ||
JP2019035603 | 2019-02-28 | ||
JP2019112619 | 2019-06-18 | ||
JP2019-112619 | 2019-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020175697A1 true WO2020175697A1 (ja) | 2020-09-03 |
Family
ID=72239799
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/008509 WO2020175697A1 (ja) | 2019-02-28 | 2020-02-28 | 3,5-二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 |
PCT/JP2020/008527 WO2020175704A1 (ja) | 2019-02-28 | 2020-02-28 | 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/008527 WO2020175704A1 (ja) | 2019-02-28 | 2020-02-28 | 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220125793A1 (ja) |
EP (2) | EP3932425A4 (ja) |
JP (4) | JPWO2020175697A1 (ja) |
KR (2) | KR20210130774A (ja) |
AU (2) | AU2020228514A1 (ja) |
MA (2) | MA55088A (ja) |
TW (2) | TW202045182A (ja) |
WO (2) | WO2020175697A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11975002B2 (en) | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | 3,5-二置換ベンゼンアルキニル化合物及びその塩 |
WO2015008844A1 (ja) * | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
WO2017150725A1 (ja) * | 2016-03-04 | 2017-09-08 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
JP2018511611A (ja) * | 2015-04-03 | 2018-04-26 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | 癌治療のためのfgfr/pd−1併用療法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040004771A (ko) | 2002-07-05 | 2004-01-16 | 삼광유리공업주식회사 | 필름 코팅 유리컵 및 그 제조방법 |
KR101480809B1 (ko) | 2012-03-26 | 2015-01-09 | 한국화학연구원 | 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말 |
CA2963281A1 (en) * | 2014-10-03 | 2016-04-07 | Novartis Ag | Combination therapies |
JP6572561B2 (ja) | 2015-03-03 | 2019-09-11 | ダイキン工業株式会社 | 熱交換器および空気調和機 |
JP2018519327A (ja) * | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドVerastem,Inc. | 治療用組成物、組合せ物および使用の方法 |
US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
JP6409797B2 (ja) | 2016-02-24 | 2018-10-24 | 三菱電機株式会社 | 冷蔵庫 |
-
2020
- 2020-02-28 EP EP20763207.6A patent/EP3932425A4/en active Pending
- 2020-02-28 KR KR1020217030409A patent/KR20210130774A/ko not_active Application Discontinuation
- 2020-02-28 MA MA055088A patent/MA55088A/fr unknown
- 2020-02-28 JP JP2021502662A patent/JPWO2020175697A1/ja active Pending
- 2020-02-28 US US17/434,573 patent/US20220125793A1/en active Pending
- 2020-02-28 EP EP20763687.9A patent/EP3932427A4/en active Pending
- 2020-02-28 WO PCT/JP2020/008509 patent/WO2020175697A1/ja unknown
- 2020-02-28 KR KR1020217030410A patent/KR20210131387A/ko not_active Application Discontinuation
- 2020-02-28 JP JP2021502667A patent/JPWO2020175704A1/ja active Pending
- 2020-02-28 MA MA055091A patent/MA55091A/fr unknown
- 2020-02-28 AU AU2020228514A patent/AU2020228514A1/en active Pending
- 2020-02-28 AU AU2020229714A patent/AU2020229714A1/en active Pending
- 2020-02-28 US US17/434,655 patent/US20220184082A1/en active Pending
- 2020-02-28 WO PCT/JP2020/008527 patent/WO2020175704A1/ja unknown
- 2020-03-02 TW TW109106772A patent/TW202045182A/zh unknown
- 2020-03-02 TW TW109106773A patent/TW202039507A/zh unknown
-
2023
- 2023-05-19 JP JP2023083174A patent/JP2023096156A/ja active Pending
- 2023-06-22 JP JP2023102852A patent/JP2023112136A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | 3,5-二置換ベンゼンアルキニル化合物及びその塩 |
WO2015008844A1 (ja) * | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
JP2018511611A (ja) * | 2015-04-03 | 2018-04-26 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | 癌治療のためのfgfr/pd−1併用療法 |
WO2017150725A1 (ja) * | 2016-03-04 | 2017-09-08 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
Non-Patent Citations (17)
Title |
---|
CANCER RES., vol. 70, 2010, pages 2085 - 2094 |
CELL, vol. 168, 2017, pages 707 - 723 |
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, vol. 33, 2014, pages 633 - 645 |
DIABODY, NAT. REV. IMMUNOL., vol. 6, 2006, pages 343 - 357 |
FRONTIERS IN IMMUNOLOGY, vol. 9, 2018 |
J. CLIN. ONCOL., vol. 24, 2006, pages 3664 - 3671 |
JCO PRECISION ONCOLOGY, 24 July 2018 (2018-07-24) |
MOL. CANCER RES., vol. 3, 2005, pages 655 - 667 |
N. ENGL. J. MED., vol. 366, 2012, pages 2443 - 2454 |
N. ENGL. J. MED., vol. 375, 2016, pages 819 - 829 |
NAT. REV. CANCER, vol. 10, 2010, pages 116 - 129 |
NAT. REV. CANCER, vol. 12, 2012, pages 252 - 264 |
ONCOTARGET, vol. 8, 2017, pages 16052 - 16074 |
SCI. TRANSL. MED., vol. 9, 2017, pages eaal 3604 |
See also references of EP3932427A4 |
THE BREAST, vol. 37, 2018, pages 126 - 133 |
W. CHOI ET AL., AACR SPECIAL CONFERENCE ON BLADDER CANCER: TRANSFORMING THE FIELD, 18 June 2019 (2019-06-18) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11975002B2 (en) | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
Also Published As
Publication number | Publication date |
---|---|
TW202039507A (zh) | 2020-11-01 |
US20220184082A1 (en) | 2022-06-16 |
EP3932427A1 (en) | 2022-01-05 |
TW202045182A (zh) | 2020-12-16 |
JPWO2020175704A1 (ja) | 2020-09-03 |
EP3932425A4 (en) | 2022-12-07 |
AU2020229714A1 (en) | 2021-10-07 |
JP2023096156A (ja) | 2023-07-06 |
EP3932425A1 (en) | 2022-01-05 |
JP2023112136A (ja) | 2023-08-10 |
MA55088A (fr) | 2022-01-05 |
EP3932427A4 (en) | 2022-12-07 |
KR20210130774A (ko) | 2021-11-01 |
JPWO2020175697A1 (ja) | 2020-09-03 |
AU2020228514A1 (en) | 2021-10-07 |
KR20210131387A (ko) | 2021-11-02 |
WO2020175704A1 (ja) | 2020-09-03 |
MA55091A (fr) | 2022-01-05 |
US20220125793A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180346586A1 (en) | Methods of treating cancer using anti-ox40 antibodies | |
JP2021181482A (ja) | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 | |
US20170000885A1 (en) | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists | |
JP2020517640A5 (ja) | ||
CN108136025A (zh) | 一种使用免疫调节治疗癌症的新颖方法 | |
WO2020175697A1 (ja) | 3,5-二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 | |
TW201625270A (zh) | 用於治療贅瘤形成的治療組合及方法 | |
JP7402691B2 (ja) | 抗cd25抗体薬物複合体による併用療法 | |
EP3697819B1 (en) | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 | |
JP2020517629A5 (ja) | ||
TWI747868B (zh) | 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑 | |
Borrie et al. | T Lymphocyte–Based Cancer Immunotherapeutics | |
US20220160718A1 (en) | Compositions and methods of treating cancer | |
CN104822703A (zh) | Igf1r和pi3k的抑制剂的组合疗法 | |
AU2020297166A1 (en) | Method for treating malignant tumor | |
US20240052430A1 (en) | Therapeutic and diagnostic methods and compositions for cancer | |
TW202320848A (zh) | 治療癌症之方法及組成物 | |
CN117715936A (zh) | 用于治疗癌症的方法和组合物 | |
CN117545857A (zh) | 用于癌症的治疗和诊断方法以及组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20763687 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021502662 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217030410 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020229714 Country of ref document: AU Date of ref document: 20200228 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020763687 Country of ref document: EP Effective date: 20210928 |